세계의 약동학 서비스 시장

Global Pharmacokinetics Services Market to Reach US$1.6 Billion by 2030

The global market for Pharmacokinetics Services estimated at US$1.0 Billion in the year 2023, is expected to reach US$1.6 Billion by 2030, growing at a CAGR of 6.5% over the analysis period 2023-2030. Small Molecules, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$1.2 Billion by the end of the analysis period. Growth in the Large Molecules segment is estimated at 7.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$271.9 Million While China is Forecast to Grow at 6.1% CAGR

The Pharmacokinetics Services market in the U.S. is estimated at US$271.9 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$249.2 Million by the year 2030 trailing a CAGR of 6.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.8% and 5.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Global Pharmacokinetics Services Market – Key Trends & Drivers Summarized

Why Are Pharmacokinetics Services Crucial in Drug Development?

Pharmacokinetics services are a fundamental component of the drug development process, playing a critical role in understanding how a drug moves through the body—its absorption, distribution, metabolism, and excretion (ADME). These services provide insights into the drug’s behavior, helping researchers determine the optimal dosage, frequency, and delivery method for therapeutic efficacy. The data generated from pharmacokinetics studies are crucial for ensuring the safety and effectiveness of new drugs before they reach clinical trials and, eventually, the market. Through detailed analysis, pharmacokinetics services assess how long a drug remains active in the system, how it is broken down in the liver, and how efficiently it is eliminated, all of which are vital for minimizing side effects and maximizing patient outcomes.

In the highly competitive pharmaceutical industry, pharmacokinetics services help reduce the risk of late-stage drug failures by identifying potential issues early in the development cycle. These services are particularly critical for drugs with narrow therapeutic windows, where precise dosing is essential to avoid toxicity or ineffective treatment. By providing a detailed map of the drug’s journey through the body, pharmacokinetics services allow for more informed decision-making in the design of clinical trials, ultimately improving the likelihood of successful regulatory approval.

How Are Technological Advancements Shaping the Pharmacokinetics Services Market?

The integration of cutting-edge technologies has transformed pharmacokinetics services, enhancing their precision, speed, and scalability. One of the most significant advancements is the use of high-throughput screening (HTS) technologies, which allow for the rapid assessment of multiple drug candidates simultaneously. HTS, combined with advanced computational models, enables more efficient prediction of a drug’s pharmacokinetics profile at earlier stages of development, reducing the need for extensive in-vivo studies and accelerating the timeline for candidate selection. Moreover, the application of artificial intelligence (AI) and machine learning (ML) has revolutionized data analysis in pharmacokinetics. AI algorithms can analyze vast datasets from pharmacokinetics studies to predict a drug’s behavior in various patient populations, offering insights that go beyond traditional statistical methods. These technologies also aid in identifying patterns that may indicate potential drug-drug interactions or adverse effects. AI-driven pharmacokinetics modeling has the potential to significantly reduce costs and time associated with drug development, allowing for more precise dosing regimens and personalized medicine approaches. Furthermore, advancements in bioanalytical techniques, such as mass spectrometry and liquid chromatography, have improved the sensitivity and accuracy of pharmacokinetics studies. These technologies allow researchers to detect and quantify drug concentrations in biological samples with greater precision, providing a more detailed understanding of how a drug is metabolized and excreted. The growing use of these technologies in pharmacokinetics services is driving the industry toward more robust and reliable data collection, which is essential for regulatory submissions and clinical trial design.

How Is Outsourcing of Pharmacokinetics Services Influencing the Market?

The outsourcing of pharmacokinetics services to specialized contract research organizations (CROs) has become a prevalent trend, as pharmaceutical and biotechnology companies look to streamline their drug development pipelines. Outsourcing allows companies to access the latest technologies, expertise, and infrastructure without the need for significant internal investments. This trend is particularly strong among small to mid-sized pharmaceutical companies, which may lack the resources to conduct in-house pharmacokinetics studies.

By partnering with CROs, these companies can take advantage of specialized pharmacokinetics services that are equipped with state-of-the-art bioanalytical tools and staffed by experts in drug metabolism and pharmacokinetics (DMPK). Outsourcing also offers the flexibility to scale services up or down based on the needs of individual drug development programs, making it a cost-effective solution for both early-stage and late-stage drug candidates. Additionally, the global reach of many CROs allows pharmaceutical companies to conduct pharmacokinetics studies across multiple geographic regions, which is crucial for addressing regulatory requirements in different markets.

Another key driver of outsourcing is the increasing complexity of new drug candidates, particularly in areas such as biologics, gene therapies, and personalized medicines. These complex therapeutics require highly specialized pharmacokinetics services, which CROs are well-positioned to provide. The rise of personalized medicine, in particular, is driving demand for pharmacokinetics studies that focus on individual variability in drug metabolism, distribution, and excretion, further fueling the growth of the outsourcing market.

What Are the Key Drivers of Growth in the Pharmacokinetics Services Market?

Growth in the pharmacokinetics services market is driven by several factors, including technological innovations, increasing complexity in drug development, and the rising trend of outsourcing. One of the primary drivers is the growing demand for personalized medicine, where pharmacokinetics studies are essential for understanding how individual genetic differences affect drug metabolism. This trend has expanded the market for pharmacokinetics services, as pharmaceutical companies require more precise and individualized data to support personalized treatment regimens. Additionally, the increasing prevalence of biologics and biosimilars in the pharmaceutical pipeline has driven demand for advanced pharmacokinetics services. These complex molecules have unique pharmacokinetics profiles, requiring specialized analysis that goes beyond traditional small-molecule drugs. As more biologics enter clinical development, the need for tailored pharmacokinetics studies will continue to grow, particularly for therapies targeting oncology, autoimmune diseases, and rare genetic disorders. The expansion of global clinical trials has also contributed to the growth of the pharmacokinetics services market. As pharmaceutical companies seek to bring drugs to market in multiple regions, they must comply with diverse regulatory requirements, necessitating region-specific pharmacokinetics data. This has led to increased demand for CROs that can conduct multi-regional studies and provide comprehensive pharmacokinetics data across various patient populations. Lastly, the regulatory landscape continues to evolve, with agencies such as the FDA and EMA placing greater emphasis on pharmacokinetics data in drug approval processes. This has driven pharmaceutical companies to invest more heavily in pharmacokinetics studies to ensure regulatory compliance and minimize the risk of late-stage clinical failures. The growing complexity of regulatory requirements, particularly for novel therapies, is expected to further propel the demand for high-quality pharmacokinetics services.

Select Competitors (Total 34 Featured) -

• Biologics Consulting Group, Inc.
• Certara L.P.
• Charles River Laboratories International, Inc.
• Creative Bioarray
• Eurofins Scientific, Inc.
• Evotec AG
• Frontage Labs
• GVK Biosciences Private Limited
• LGC Limited
• Pacific BioLabs
• Parexel International Corporation
• Pharmaceutical Product Development, LLC
• Product Development, LLC (Jaguar Holding Company I, LLC)
• SGS SA
• Shanghai Medicilon Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Global Economic Update
  • Pharmacokinetics Services - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Demand for Pharmacokinetics Services in Drug Discovery and Development Drives Growth in Outsourced Research Support
  • Increasing Focus on Personalized Medicine and Tailored Therapies Propels Growth in Pharmacokinetics Studies for Customized Treatment Plans
  • Expansion of Biologics, Biosimilars, and Advanced Therapeutics Strengthens Demand for Pharmacokinetics Services in Preclinical and Clinical Trials
  • Technological Advancements in Pharmacokinetic Modeling and Simulation Tools Enhance Drug Development Efficiency and Predictive Accuracy
  • Growing Adoption of In Silico and In Vitro Pharmacokinetics Methods Expands Market for Non-Animal Testing Alternatives
  • Rising Stringency of Regulatory Requirements for Drug Absorption, Distribution, Metabolism, and Excretion (ADME) Testing Drives Growth in Pharmacokinetics Services
  • Increased Focus on Safety and Efficacy Testing for New Drug Applications Fuels Demand for Comprehensive Pharmacokinetics Studies
  • Growing Use of Pharmacokinetics in Determining Drug Dosing, Bioavailability, and Toxicity Profiles in Early-Stage Development
  • Emerging Use of Population Pharmacokinetics to Support Clinical Decision-Making and Dose Optimization in Specific Patient Populations
  • Rising Need for Pharmacokinetics Services in the Development of Orphan Drugs and Rare Disease Therapies
  • Technological Innovations in LC-MS/MS and Other Bioanalytical Techniques Enhance Data Accuracy in Pharmacokinetics Studies
  • Increased Outsourcing of Pharmacokinetics Studies to Contract Research Organizations (CROs) for Cost Efficiency and Expertise
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Pharmacokinetics Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 2: World Historic Review for Pharmacokinetics Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 3: World 16-Year Perspective for Pharmacokinetics Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Small Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 5: World Historic Review for Small Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 6: World 16-Year Perspective for Small Molecules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 7: World Recent Past, Current & Future Analysis for Large Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 8: World Historic Review for Large Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 9: World 16-Year Perspective for Large Molecules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 10: World Pharmacokinetics Services Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Pharmacokinetics Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 11: USA Recent Past, Current & Future Analysis for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 12: USA Historic Review for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 13: USA 16-Year Perspective for Pharmacokinetics Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 14: Canada Recent Past, Current & Future Analysis for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 15: Canada Historic Review for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 16: Canada 16-Year Perspective for Pharmacokinetics Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2014, 2024 & 2030
• JAPAN
  • Pharmacokinetics Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 17: Japan Recent Past, Current & Future Analysis for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 18: Japan Historic Review for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 19: Japan 16-Year Perspective for Pharmacokinetics Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2014, 2024 & 2030
• CHINA
  • Pharmacokinetics Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 20: China Recent Past, Current & Future Analysis for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 21: China Historic Review for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 22: China 16-Year Perspective for Pharmacokinetics Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2014, 2024 & 2030
• EUROPE
  • Pharmacokinetics Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 23: Europe Recent Past, Current & Future Analysis for Pharmacokinetics Services by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 24: Europe Historic Review for Pharmacokinetics Services by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 25: Europe 16-Year Perspective for Pharmacokinetics Services by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 26: Europe Recent Past, Current & Future Analysis for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 27: Europe Historic Review for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 28: Europe 16-Year Perspective for Pharmacokinetics Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2014, 2024 & 2030
• FRANCE
  • Pharmacokinetics Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 29: France Recent Past, Current & Future Analysis for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 30: France Historic Review for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 31: France 16-Year Perspective for Pharmacokinetics Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2014, 2024 & 2030
• GERMANY
  • Pharmacokinetics Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 32: Germany Recent Past, Current & Future Analysis for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 33: Germany Historic Review for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 34: Germany 16-Year Perspective for Pharmacokinetics Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 35: Italy Recent Past, Current & Future Analysis for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 36: Italy Historic Review for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 37: Italy 16-Year Perspective for Pharmacokinetics Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Pharmacokinetics Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 38: UK Recent Past, Current & Future Analysis for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 39: UK Historic Review for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 40: UK 16-Year Perspective for Pharmacokinetics Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 41: Rest of Europe Recent Past, Current & Future Analysis for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 42: Rest of Europe Historic Review for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 43: Rest of Europe 16-Year Perspective for Pharmacokinetics Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Pharmacokinetics Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 44: Asia-Pacific Recent Past, Current & Future Analysis for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 45: Asia-Pacific Historic Review for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 46: Asia-Pacific 16-Year Perspective for Pharmacokinetics Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2014, 2024 & 2030
• REST OF WORLD
  • TABLE 47: Rest of World Recent Past, Current & Future Analysis for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 48: Rest of World Historic Review for Pharmacokinetics Services by Drug Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 49: Rest of World 16-Year Perspective for Pharmacokinetics Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2014, 2024 & 2030

IV. COMPETITION